Retinal cases & brief reports · 2026
ADJUNCTIVE INTRAVITREAL MOXIFLOXACIN AND RANIBIZUMAB IN THE MANAGEMENT OF INTRAOCULAR TUBERCULOMA.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pant Nehali, Raman Rajiv, Biswas Jyotirmay
Аннотация
PURPOSE: To evaluate the role of adjunctive intravitreal moxifloxacin and ranibizumab in the management of recalcitrant and treatment-naive cases of intraocular tuberculoma.
METHODS: The study included 10 eyes of nine patients diagnosed with intraocular tuberculoma between June 2022 and March 2025 at a tertiary eye care center in India. All patients received systemic therapy and biweekly intravitreal injections of moxifloxacin (500 µg/0.1 mL) and ranibizumab (0.5 mg/0.05 mL) until clinical and anatomical regression of the tuberculoma. Patients were stratified into two groups: Group A (recalcitrant cases) and Group B (treatment-naive cases). Data on imaging features, number of injections, and visual acuity outcomes were analyzed.
RESULTS: Group A cases (n = 3) had peripheral or ciliary body granulomas and received a 9-month ethambutol-sparing antitubercular treatment regimen along with local therapy. Two eyes achieved a final visual acuity of 6/6, whereas one developed cataract with secondary angle closure glaucoma. Group B (n = 7) included four macular granulomas and three cases with panuveitis and peripheral lesions. The three macular cases required fewer than three injections, achieving 6/6 visual outcomes. Two cases experienced reactivation and responded well to repeat local and systemic therapy.
CONCLUSION: Adjunctive intravitreal moxifloxacin and ranibizumab, when combined with systemic antitubercular treatment and corticosteroids, appears to be a valuable therapeutic option in the management of intraocular tuberculoma, especially in cases with macular involvement. Tailored local therapy based on clinical phenotype may enhance lesion control and reduce systemic treatment duration.
METHODS: The study included 10 eyes of nine patients diagnosed with intraocular tuberculoma between June 2022 and March 2025 at a tertiary eye care center in India. All patients received systemic therapy and biweekly intravitreal injections of moxifloxacin (500 µg/0.1 mL) and ranibizumab (0.5 mg/0.05 mL) until clinical and anatomical regression of the tuberculoma. Patients were stratified into two groups: Group A (recalcitrant cases) and Group B (treatment-naive cases). Data on imaging features, number of injections, and visual acuity outcomes were analyzed.
RESULTS: Group A cases (n = 3) had peripheral or ciliary body granulomas and received a 9-month ethambutol-sparing antitubercular treatment regimen along with local therapy. Two eyes achieved a final visual acuity of 6/6, whereas one developed cataract with secondary angle closure glaucoma. Group B (n = 7) included four macular granulomas and three cases with panuveitis and peripheral lesions. The three macular cases required fewer than three injections, achieving 6/6 visual outcomes. Two cases experienced reactivation and responded well to repeat local and systemic therapy.
CONCLUSION: Adjunctive intravitreal moxifloxacin and ranibizumab, when combined with systemic antitubercular treatment and corticosteroids, appears to be a valuable therapeutic option in the management of intraocular tuberculoma, especially in cases with macular involvement. Tailored local therapy based on clinical phenotype may enhance lesion control and reduce systemic treatment duration.